Skip to main content
Skip to footer
Opens in a new tab
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
About
Our Philosophy
Meet Our Care Team
Your Care Experience
Services
Cancer Care
Laboratory Services
Same-Day CT Imaging
Liberty Pharmacy
Infusion Services
Clinical Trials
Is a Clinical Trial Right for Me?
Find a Clinical Trial
Frequently Asked Questions
About PhaseWell Research
Resources
Patient Resources
Patient Forms
Billing & Insurance
Educational Resources
Approved Oncology Drugs (PDF)
Referring Physicians
Contact Us
Category:
Multiple Myeloma
A Phase 3, Randomized, Open-label Study of Belantamab Mafodotin with Lenalidomide and Dexamethasone (BRd) vs Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Newly Diagnosed Multiple Myeloma Ineligible for Autologous Stem Cell Transplantation (DREAMM-10)
September 11, 2026
A Single-arm, Open-label, Phase 2 Study of Subcutaneous Isatuximab via On-Body Delivery System with Weekly Carfilzomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma (RRMM)
September 11, 2026
A Protocol to Assess the Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Low-Dose Lenalidomide (STAR-LLD) for the Treatment of Multiple Myeloma
September 11, 2026
A Phase 1/2 Open-label, Multicentre, Dose Escalation and Expansion Study of Belantamab as Monotherapy and in Combination with Other Treatments in Multiple Myeloma
September 11, 2026
A Randomized, Multi-Center, Double-Blinded, Placebo-Controlled Trial of XEMBIFY plus Standard Medical Treatment vs Placebo to Prevent Infections in Hypogammaglobulinemia with CLL, Multiple Myeloma, and Non-Hodgkin Lymphoma
September 11, 2026
